Page 40 - Compass Pathways News Today

Psychedelic psilocybin in magic mushrooms outperformed leading depression treatment Psilocybin appeared to treat depression more quickly, for longer and with few side effects than antidepressant escitalopram. Updated Subscribe When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice. Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice The psychedelic drug found in magic ...

The psychedelic compound found in magic mushrooms may be at least as effective as a leading antidepressant medication in a therapeutic setting, a new study suggests. Researchers compared the therapeutic potential of psilocybin – found in the mushrooms – with a six-week course of the antidepressant escitalopram in 59 people with moderate to severe depression. They found that, while depression scores were reduced in both groups, the reductions occurred more quickly in the psilocybin group and...

Imperial College London scientists just published a report on how psychedelics could treat depression. The study pits psilocybin, the active compound in magic mushrooms, against the depression drug escitalopram. Reduction in depression occurred more quickly with psilocybin, but the differences were not significant. In recent years, research into the use of psychedelics for the treatment of mental-health illnesses has begun to thrive. Private companies focused on developing psychedelics-based me...

Biotech Companies Driving Psychedelics Industry Forward with Key Research FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 13, 2021 /PRNewswire/ -- As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted therapies are showing huge potential. Now, biotech companies have seen the opportunity, and psychedelics companies are diving into further research to seek ...

Mind Medicine (OTC:MMEDF) and Mydecine Innovations Group Inc (OTC:MYCOF) often following its moves. After reaching an all-time high of $61.69 on Dec. 14, Compass Pathways consolidated for seven weeks before making another big push to the upside on Feb. 22. After failing to reach a new high on the push, it’s been in a sharp decline, plummeting 37% over the past six weeks. The sector may be in for a turnaround, however, as Compass Pathway’s stock is starting to flash bullish signals. The Com...

Aikido Pharma Inc. (NASDAQ: AIKI)Penny Stocks To Watch #1: Havn Life Sciences (OTC: HAVLF) (CSE: HAVN) Many of these psychedelic-focused companies are working on R&D., But few of them have notable names that helped carve out prior “fringe industries” like cannabis. In Havn’s case, the former CEO of Aphria (NASDAQ: APHA), Vic Neufeld, sits as the Executive Chairman. Other Aphria alumni like Gary Long, its Chief Scientific Officer, was Aphria’s former CSO. Other C-level member...

Seelos Therapeutics (NASDAQ: SEEL)Penny Stocks To Watch With Strong Leadership: Havn Life Sciences (OTC: HAVLF) I mentioned that some of the former trailblazers of cannabis got involved in psychedelics. Havn is one of the companies that fit the mold. While its management team comprises financial markets professionals like CEO Tim Moore and Eli Dusenbury, its makeup also includes names that were part of the early cannabis boom. For instance, Gary Long, its Chief Scientific Officer, was the forme...

Peptilogics Strengthens Leadership Team with Three Strategic Appointments - Dr. David Huang, leader in anti-infective drug development, to serve as SVP, Chief Medical Officer - Dr. Nick Nystrom, global leader in life sciences AI, to serve as SVP, Computing & Data - Nicholas Pachuda, seasoned expert in business strategy, to serve as SVP, Portfolio Strategy & Development News provided by Share this article Share this article PITTSBURGH, March 17, 2021 /PRNewswire/ -- Peptilogics, a biotechnology...

Carr has spent a lot of time evaluating the investment opportunity in cannabis, which is another trendy drug market. He told INN that while the psychedelics and cannabis markets operate in very different ways, he has noticed some similarities between them. “Right now, the psychedelic medicine market feels like the cannabis market a decade ago,” he said, describing the current crop of early stage psychedelics companies trying to get the ball rolling on the development of a new regulated drug...

Article content Toronto-based Field Trip Health Ltd., has announced it has closed a common share deal worth $95 million. The lead investor was Soleus Capital, a private equity firm based in Greenwich, Conn. Additionally, Avidity Partners, Sphera Funds, Pura Vida Investments, Jennison Associates and other healthcare-specialized institutional investors took part in the deal. We apologize, but this video has failed to load. Try refreshing your browser, or Field Trip Health announces closing of fi...